Amol Akhade: cfDNA Multi-Cancer Detection (MCD) Tests – Hype, Hope, or Halfway There?
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“cfDNA Multi-Cancer Detection (MCD) Tests: Hype, Hope, or Halfway There?
Insights from ESMOGI25
Blood-based MCD tests are being hailed as the future of early cancer detection—especially for cancers without established screening tools. But are we there yet?
Here’s the reality check:
Promise – Especially in hard-to-screen cancers like pancreatic, biliary, and ovarian.
Problem – Sensitivity in early-stage disease remains inadequate.
Risk – High false-positive rates can lead to anxiety, over-testing, and harm.
Reality – These tests are not a replacement for standard screening protocols.
Unknown – Whether they reduce cancer-related mortality is still unproven.
Bottom line:
MCD tests hold real potential – but clinical utility and mortality benefit are not yet established. Until then, they must be seen as complementary, not disruptive.
As oncologists, let’s stay excited – but grounded.”
More Posts Featuring Amol Akhade on Oncodaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023